ASRT Assertio Holdings, Inc.


$ 0.72 $ 0.00 (0 %)    

Friday, 21-Nov-2025 14:22:47 EST
QQQ $ 596.75 $ 9.42 (1.6 %)
DIA $ 465.42 $ 5.95 (1.29 %)
SPY $ 664.32 $ 9.31 (1.42 %)
TLT $ 89.34 $ -0.32 (-0.36 %)
GLD $ 375.93 $ 1.92 (0.51 %)
$ na
$ 0.73
$ 0.72 x 700
$ 0.72 x 4,506
$ 0.72 - $ 0.74
$ 0.51 - $ 1.08
525,273
na
69.78M
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 assertio-holdings-narrows-fy2025-sales-guidance-from-108000m-118000m-to-110000m-112000m-vs-111089m-est

Assertio Holdings (NASDAQ:ASRT) narrows FY2025 sales outlook from $108.000 million-$118.000 million to $110.000 million-$112.00...

 assertio-holdings-q3-adj-eps-018-beats-009-estimate-sales-49459m-beat-27020m-estimate

Assertio Holdings (NASDAQ:ASRT) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $(0...

 assertio-appoints-mark-l-reisenauer-as-ceo-effective-immediately-succeeding-brendan-p-ogrady

Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), today announced that its Board of Directo...

 assertio-presents-data-on-sympazan-showing-how-it-is-being-used-in-daily-clinical-practice-to-treat-patients-with-lennox-gastaut-syndrome

New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a sev...

 assertio-holdings-will-present-new-data-for-sympazan-clobazam-at-the-annual-meeting-of-the-american-neurological-association

Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive ...

 hc-wainwright--co-maintains-buy-on-assertio-holdings-lowers-price-target-to-3

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Assertio Holdings (NASDAQ:ASRT) with a Buy and lowers the price...

 assertio-holdings-narrows-fy2025-sales-guidance-from-10800m-12300m-to-10800m-11800m-vs-11372m-est

Assertio Holdings (NASDAQ:ASRT) narrows FY2025 sales outlook from $108.00 million-$123.00 million to $108.00 million-$118.00 mi...

 assertio-holdings-q2-adj-eps-002-beats-008-estimate-sales-2922m-beat-2786m-estimate

Assertio Holdings (NASDAQ:ASRT) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-reiterates-buy-on-assertio-holdings-maintains-35-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Assertio Holdings (NASDAQ:ASRT) with a Buy and maintains $3.5 ...

 assertio-holdings-q1-adj-eps-004-beats-006-estimate-sales-2649m-miss-2752m-estimate

Assertio Holdings (NASDAQ:ASRT) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-maintains-buy-on-assertio-holdings-lowers-price-target-to-35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Assertio Holdings (NASDAQ:ASRT) with a Buy and lowers the price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION